Literature DB >> 22378078

Implementing human papillomavirus testing in a public health hospital: challenges and opportunities.

Mariana Carmezim Beldi1, Maricy Tacla, Helio Caiaffa-Filho, Alexandre Ab'saber, Sheila Siqueira, Edmund Chada Baracat, Venancio Avancini Ferreira Alves, Adhemar Longatto-Filho.   

Abstract

OBJECTIVES: Robust evidence now supports human papillomavirus (HPV) testing as a more effective option to screening and as more sensitive than cytology in detecting high-grade cervical intraepithelial neoplasia . Our goal was to analyze the performance of the Hybrid Capture II (HC2) assay for high-risk HPV (hrHPV) in women undergoing gynecological examination at a public health hospital as part of the evaluation of HPV screening as an alternative or complement to cytology. STUDY
DESIGN: This analysis is a subset of a cross-sectional study carried out at a large public hospital serving a predominantly low-resource population. A total of 705 women were enrolled; the sensitivity and specificity of each test were estimated and compared.
RESULTS: The analysis identified 272 hrHPV-positive women (mean age 36.3 years) and 433 hrHPV-negative women (mean age 41.2 years). HPV testing showed a significantly increased sensitivity of the HC2 assay versus cytology (84.5 vs. 69.7%; p < 0.0001) but a lower specificity (49.90 vs. 88.78%; p < 0.0001).
CONCLUSION: The combination of both methods seems to be useful in improving detection of cervical lesions.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22378078     DOI: 10.1159/000335145

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  1 in total

1.  Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: an observational study.

Authors:  Mariana G Waisberg; Ana C M Ribeiro; Wellington M Candido; Poliana B Medeiros; Cezar N Matsuzaki; Mariana C Beldi; Maricy Tacla; Helio H Caiaffa-Filho; Eloísa Bonfa; Clovis A Silva
Journal:  Rheumatol Int       Date:  2014-10-28       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.